The first trial in the Pennsylvania state court litigation against the makers of Xarelto, Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, started on Nov. 6 and the case should be very close to a verdict. Plaintiff Lynn Hartman claims that Xarelto caused her to suffer internal gastrointestinal bleeding while she was taking Xarelto for atrial fibrillation. As a result of the bleed, Ms. Hartman spent several days in the hospital and was forced to undergo multiple blood transfusions. Plaintiff alleges that the makers of Xarelto failed to warn doctors and patients that the risk of bleeding on Xarelto doubles if Xarelto is used in conjunction with aspirin.
Plaintiff claims further that Bayer and Janssen failed to inform doctors that Xarelto’s clinical trials showed that patients in the U.S. had a 50 percent increased risk of bleeding in Xarelto’s primary clinical trial. Ms. Hartman claims that if the Defendants would have told her and her doctors the whole truth about Xarelto’s risks, she would not have taken Xarelto and her bleed would not have occurred. Ms. Hartman’s trial is expected to conclude by early December.
Ms. Hartman’s trial is the first of about 2,000 cases pending in the Philadelphia Court of Common Pleas against the makers of Xarelto. Two additional trials are scheduled to start in Philadelphia in January 2018, and several additional trials are expected next year. In addition to the Philadelphia Xarelto litigation, the Xarelto multidistrict litigation (MDL) under Judge Eldon Fallon in the Eastern District of Louisiana is ongoing as well, with approximately 20,000 pending cases. Beasley Allen lawyers continue to be actively involved in both the Pennsylvania state court litigation and the MDL.